Public disclosure of inside information according to article 17 MAR
Leverkusen (pta029/24.09.2025/23:10) - "
| Biofrontera AG: Expected impairment losses in the unconsolidated accounts amounting to approx. €50 million to €65 million, consolidated net earnings in 2025 expected to be around €5 million lower | |
| As of today, the Management Board expects, with a high degree of likelihood, that Biofrontera AG will be required to recognize a significant write-down in ist unconsolidated accounts on the valuations of its subsidiaries, Biofrontera Pharma GmbH and Biofrontera Bioscience GmbH, in an amount expected to range between €50 million and €65 million. | |
| Based on the current information regarding associated risks across the different markets, the management has reduced the profit expectations of both subsidiaries. The downward revision of expected profitability has a direct impact on the carrying value of the investments and, consequently, on the equity of Biofrontera AG. The exact amount of the write-down will be determined in the course of preparing the unconsolidated financial statements as of December 31, 2025. | |
| In addition, the reduction in projected future results adversely affects the recoverability of deferred tax assets, which will result in a negative impact on the Group's net consolidated results (IFRS) by presumably around €5 million. | |
| None of these effects will impact consolidated EBITDA for 2025, either at half-year or year-end 2025, and will not affect the Company's cash position." | |
(end)
emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com
ISIN(s): DE000A4BGGM7 (share)
stock exchanges: regulated market in Dusseldorf, Frankfurt; free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate